Komal Akhtar Metlapalli Venkata Sravanthi Josephine D'Angelo Abirami Sivapiragasam
10.1177/23247096221121408
J Investig Med High Impact Case Rep
2022 Jan-Dec;10:23247096221121408.
pd-1 cscc cemiplimab cutaneous squamous cell carcinoma immunotherapy programmed death receptor 1
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/36017984/
Carcinoma, Squamous Cell / drug therapy Carcinoma, Squamous Cell / pathology Skin Neoplasms / drug therapy Skin Neoplasms / pathology
Carcinoma, Squamous Cell / drug therapy Carcinoma, Squamous Cell / pathology Skin Neoplasms / drug therapy Skin Neoplasms / pathology Aged Antibodies, Monoclonal, Humanized / therapeutic use Humans Male Neoplasm Recurrence, Local Antibodies, Monoclonal, Humanized cemiplimab
PMC9421057
36017984
Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
2022